Search the Newsreel

Apogee Therapeutics Inc (APGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Apogee Therapeutics Inc (APGE), detailing its support, resistance, indicators, and moving averages. According to TradingKey, the overall technical signal for APGE is Neutral, with specific indicators showing mixed signals (e.g., RSI and Williams %R are Overbought, while …

Apogee Therapeutics Inc (APGE) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Apogee Therapeutics Inc (APGE), focusing on its PE, PB, and fair value. It displays current market data including the stock price, daily change, market capitalization, and a placeholder for P/E TTM, suggesting that detailed financial analysis is …

First Light Asset Management LLC Increases Stock Holdings in Apogee Therapeutics Inc. $APGE

Apogee Therapeutics Inc (APGE) Institutional Confidence

This article from TradingKey provides an overview of Apogee Therapeutics Inc.'s (APGE) institutional confidence, detailing major institutional shareholders and their recent activity. Key investors like T. Rowe Price Investment Management, Inc., VR Adviser, LLC, and Fidelity Management & Research Company LLC are listed along …

Apogee Therapeutics Inc (APGE) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Apogee Therapeutics Inc (APGE), detailing its volatility, financial risk, and investment risk metrics. It includes data on beta, Value at Risk (VaR), maximum drawdown, volatility, return statistics, Sharpe ratio, and liquidity measures over various timeframes. The information …

Apogee Therapeutics Inc (APGE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Apogee Therapeutics Inc (APGE), highlighting current analyst ratings, target prices, and historical and projected EPS. Based on 15 analysts, the stock currently holds a "Hold" rating with an expected upside space of -2.75%. The article also includes …

Apogee Therapeutics Inc (APGE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Apogee Therapeutics Inc (APGE), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types and a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over …

Apogee Therapeutics Inc (APGE) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial analysis of Apogee Therapeutics Inc (APGE), focusing on its profitability and balance sheet. It presents key financial data such as its market capitalization and current stock price. The content is primarily a placeholder for a detailed financial report that …

Granahan Investment Management LLC Has $6.32 Million Stock Position in Apogee Therapeutics Inc. $APGE

Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Apogee Therapeutics Inc (APGE) for transactions that occurred on July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a …

Apogee Therapeutics (APGE) CFO makes bona fide gift of 15,000 shares

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, reported a bona fide gift of 15,000 shares of common stock to a donor-advised fund. This transaction was not executed under a Rule 10b5-1 plan, and following the transfer, Henderson directly holds 158,371 shares of APGE. The …

Understanding Momentum Shifts in (APGE)

This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE), noting neutral near and mid-term readings but a positive long-term bias. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details AI-generated institutional trading strategies (Position, Momentum Breakout, …

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

AbbVie (NYSE: ABBV) has performed fairly well this year despite significant volatility. The company's shares are up 10%, slightly above the S&P 500's 8% return. Will the healthcare leader maintain this momentum? Some may worry that AbbVie faces significant near-term risks, given the continued …

Apogee Therapeutics stock hits all-time high at 134.34 USD

Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements …

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

Key Points AbbVie will fund this acquisition with debt, leaving its cash reserves intact. The company should maintain its dividend program as it did after previous massive acquisitions. 10 stocks we like better than AbbVie › On June 22, AbbVie(NYSE: ABBV) announced that it …

Fifth Third Bancorp Takes $5.37 Million Position in Apogee Therapeutics Inc. $APGE

Apogee Therapeutics (APGE) Proxy filing Summary

This article summarizes the proxy filing for Apogee Therapeutics (APGE), detailing the upcoming annual meeting on June 9, 2026. Key agenda items include the election of three Class III directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote …

Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com

This Investing.com article reports on a Form 4 filing for Apogee Therapeutics Inc. dated July 16. It includes stock market data for various indices, commodities, bonds, and individual shares, alongside popular articles and market movers. The article is brief, primarily serving as a notification …

Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund as a non-market disposition at $0.00 per share. Following this transaction, Dambkowski directly holds 169,873 …

APGE Forecast — Price Target — Prediction for 2027

Apogee Therapeutics (APGE) surges 46.7% in active-mover trading

The biotechnology stock’s move puts fresh focus on a recent weekly advance that had already been building before the latest screen spike.

Stocks making the biggest moves midday: Alphabet, AeroVironment, Salesforce, Apogee Therapeutics & more

Capgemini : Son grand rival Accenture s'effondre à Wall Street après des résultats décevants, Capgemini plonge de 8% en Bourse, lanterne rouge du CAC 40

APGE Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Modest Stock Gains - Cash Flow Report

Hear Apogee Therapeutics' June fireside talks at Jefferies and Goldman

APGE Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Surprise - Free Cash Flow Trends

Apogee biotech with $902.9M cash eyes possible 2029 atopic dermatitis drug

Résultats de Capgemini : les revenus du quatrième trimestre ont dépassé les prévisions

Capgemini : un tournant dans la croissance pourrait être atteint ; les actions sont sous-évaluées

Le géant français des services numériques, Capgemini, a dépassé les attentes du marché et ses prévisions au premier trimestre malgré l'environnement incertain

Capgemini SE: Bewertungskennzahlen, Analystenprognosen

Capgemini SE: Finanzdaten Prognosen Schätzungen und Erwartungen | 869858 | FR0000125338

Capgemini SE: Prévisions et Estimations des Analystes | CAP

Apogee Therapeutics, Inc. (APGE) stock price, news, quote and history

Capgemini SE: Konsensus der Analysten und Kursziel | 869858 | FR0000125338